nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—chronic obstructive pulmonary disease	0.193	0.509	CbGaD
Bortezomib—CYP1A2—chronic obstructive pulmonary disease	0.186	0.491	CbGaD
Bortezomib—PTGS1—Montelukast—chronic obstructive pulmonary disease	0.0399	0.126	CbGbCtD
Bortezomib—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0255	0.0805	CbGbCtD
Bortezomib—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0255	0.0805	CbGbCtD
Bortezomib—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.023	0.0727	CbGbCtD
Bortezomib—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0212	0.0669	CbGbCtD
Bortezomib—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0212	0.0669	CbGbCtD
Bortezomib—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.02	0.0631	CbGbCtD
Bortezomib—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0194	0.0612	CbGbCtD
Bortezomib—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0194	0.0612	CbGbCtD
Bortezomib—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0173	0.0545	CbGbCtD
Bortezomib—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0163	0.0513	CbGbCtD
Bortezomib—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0161	0.0507	CbGbCtD
Bortezomib—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.011	0.0347	CbGbCtD
Bortezomib—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0107	0.0338	CbGbCtD
Bortezomib—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0105	0.0331	CbGbCtD
Bortezomib—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00934	0.0295	CbGbCtD
Bortezomib—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00548	0.0173	CbGbCtD
Bortezomib—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00518	0.0163	CbGbCtD
Bortezomib—CTSG—respiratory system—chronic obstructive pulmonary disease	0.00301	0.047	CbGeAlD
Bortezomib—PSMA1—respiratory system—chronic obstructive pulmonary disease	0.00289	0.0451	CbGeAlD
Bortezomib—CTSG—connective tissue—chronic obstructive pulmonary disease	0.00265	0.0414	CbGeAlD
Bortezomib—PSMA1—connective tissue—chronic obstructive pulmonary disease	0.00255	0.0397	CbGeAlD
Bortezomib—CTSG—trachea—chronic obstructive pulmonary disease	0.00223	0.0347	CbGeAlD
Bortezomib—PSMD2—respiratory system—chronic obstructive pulmonary disease	0.00215	0.0335	CbGeAlD
Bortezomib—PSMD1—bronchus—chronic obstructive pulmonary disease	0.002	0.0312	CbGeAlD
Bortezomib—PSMD1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00195	0.0305	CbGeAlD
Bortezomib—PSMD1—trachea—chronic obstructive pulmonary disease	0.00179	0.028	CbGeAlD
Bortezomib—PSMD2—bronchus—chronic obstructive pulmonary disease	0.00177	0.0276	CbGeAlD
Bortezomib—PSMB8—bronchus—chronic obstructive pulmonary disease	0.00176	0.0274	CbGeAlD
Bortezomib—PSMD2—smooth muscle tissue—chronic obstructive pulmonary disease	0.00173	0.027	CbGeAlD
Bortezomib—PSMB1—respiratory system—chronic obstructive pulmonary disease	0.00165	0.0257	CbGeAlD
Bortezomib—PSMB2—respiratory system—chronic obstructive pulmonary disease	0.00161	0.0251	CbGeAlD
Bortezomib—CTSG—lung—chronic obstructive pulmonary disease	0.0016	0.0249	CbGeAlD
Bortezomib—PSMD2—trachea—chronic obstructive pulmonary disease	0.00159	0.0248	CbGeAlD
Bortezomib—PSMB8—trachea—chronic obstructive pulmonary disease	0.00158	0.0246	CbGeAlD
Bortezomib—PSMB5—bronchus—chronic obstructive pulmonary disease	0.00155	0.0242	CbGeAlD
Bortezomib—PSMA1—lung—chronic obstructive pulmonary disease	0.00154	0.0239	CbGeAlD
Bortezomib—PSMB5—smooth muscle tissue—chronic obstructive pulmonary disease	0.00152	0.0237	CbGeAlD
Bortezomib—PSMB2—connective tissue—chronic obstructive pulmonary disease	0.00142	0.0221	CbGeAlD
Bortezomib—PSMB5—trachea—chronic obstructive pulmonary disease	0.0014	0.0218	CbGeAlD
Bortezomib—SLC31A1—respiratory system—chronic obstructive pulmonary disease	0.00139	0.0217	CbGeAlD
Bortezomib—PSMB1—bronchus—chronic obstructive pulmonary disease	0.00136	0.0212	CbGeAlD
Bortezomib—PSMB1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00133	0.0207	CbGeAlD
Bortezomib—PSMB2—bronchus—chronic obstructive pulmonary disease	0.00133	0.0207	CbGeAlD
Bortezomib—PSMB2—smooth muscle tissue—chronic obstructive pulmonary disease	0.0013	0.0202	CbGeAlD
Bortezomib—PSMD1—lung—chronic obstructive pulmonary disease	0.00129	0.0201	CbGeAlD
Bortezomib—PSMB1—trachea—chronic obstructive pulmonary disease	0.00122	0.019	CbGeAlD
Bortezomib—PSMB2—trachea—chronic obstructive pulmonary disease	0.00119	0.0186	CbGeAlD
Bortezomib—SLC31A1—bronchus—chronic obstructive pulmonary disease	0.00115	0.0179	CbGeAlD
Bortezomib—PSMD2—lung—chronic obstructive pulmonary disease	0.00114	0.0178	CbGeAlD
Bortezomib—PSMB8—lung—chronic obstructive pulmonary disease	0.00113	0.0177	CbGeAlD
Bortezomib—SLC31A1—trachea—chronic obstructive pulmonary disease	0.00103	0.0161	CbGeAlD
Bortezomib—PSMB5—lung—chronic obstructive pulmonary disease	0.001	0.0156	CbGeAlD
Bortezomib—PSMB1—lung—chronic obstructive pulmonary disease	0.000876	0.0137	CbGeAlD
Bortezomib—PSMB2—lung—chronic obstructive pulmonary disease	0.000855	0.0133	CbGeAlD
Bortezomib—SLC31A1—lung—chronic obstructive pulmonary disease	0.00074	0.0115	CbGeAlD
Bortezomib—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.00048	0.00749	CbGeAlD
Bortezomib—CYP1A1—respiratory system—chronic obstructive pulmonary disease	0.000474	0.00739	CbGeAlD
Bortezomib—PTGS1—respiratory system—chronic obstructive pulmonary disease	0.000416	0.00649	CbGeAlD
Bortezomib—CYP1A1—bronchus—chronic obstructive pulmonary disease	0.00039	0.00608	CbGeAlD
Bortezomib—PTGS1—connective tissue—chronic obstructive pulmonary disease	0.000366	0.00571	CbGeAlD
Bortezomib—CYP1A1—trachea—chronic obstructive pulmonary disease	0.00035	0.00546	CbGeAlD
Bortezomib—PSMB8—Medrysone—Prednisolone—chronic obstructive pulmonary disease	0.000347	0.146	CbGdCrCtD
Bortezomib—PTGS1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000335	0.00523	CbGeAlD
Bortezomib—PTGS1—trachea—chronic obstructive pulmonary disease	0.000307	0.0048	CbGeAlD
Bortezomib—PSMB8—Fluorometholone—Prednisone—chronic obstructive pulmonary disease	0.000257	0.108	CbGdCrCtD
Bortezomib—CYP1A2—lung—chronic obstructive pulmonary disease	0.000255	0.00398	CbGeAlD
Bortezomib—CYP1A1—lung—chronic obstructive pulmonary disease	0.000251	0.00392	CbGeAlD
Bortezomib—PSMB8—Fluorometholone—Prednisolone—chronic obstructive pulmonary disease	0.000251	0.106	CbGdCrCtD
Bortezomib—PTGS1—lung—chronic obstructive pulmonary disease	0.000221	0.00345	CbGeAlD
Bortezomib—PSMB8—Diflorasone—Prednisone—chronic obstructive pulmonary disease	0.000196	0.0826	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisolone—chronic obstructive pulmonary disease	0.000191	0.0806	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisone—chronic obstructive pulmonary disease	0.000181	0.0763	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisone—chronic obstructive pulmonary disease	0.000181	0.0763	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000177	0.0745	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000177	0.0745	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisone—chronic obstructive pulmonary disease	0.000105	0.0443	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Prednisone—chronic obstructive pulmonary disease	0.000105	0.0443	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.0432	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.0432	CbGdCrCtD
Bortezomib—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	8.79e-05	0.000605	CcSEcCtD
Bortezomib—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	8.78e-05	0.000604	CcSEcCtD
Bortezomib—Sepsis—Prednisone—chronic obstructive pulmonary disease	8.77e-05	0.000604	CcSEcCtD
Bortezomib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	8.72e-05	0.0006	CcSEcCtD
Bortezomib—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	8.65e-05	0.000595	CcSEcCtD
Bortezomib—Oedema—Salbutamol—chronic obstructive pulmonary disease	8.65e-05	0.000595	CcSEcCtD
Bortezomib—Infection—Salbutamol—chronic obstructive pulmonary disease	8.59e-05	0.000591	CcSEcCtD
Bortezomib—Hypotension—Formoterol—chronic obstructive pulmonary disease	8.56e-05	0.000589	CcSEcCtD
Bortezomib—Hypotension—Arformoterol—chronic obstructive pulmonary disease	8.56e-05	0.000589	CcSEcCtD
Bortezomib—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	8.55e-05	0.000589	CcSEcCtD
Bortezomib—Pruritus—Aminophylline—chronic obstructive pulmonary disease	8.52e-05	0.000586	CcSEcCtD
Bortezomib—Shock—Salbutamol—chronic obstructive pulmonary disease	8.51e-05	0.000586	CcSEcCtD
Bortezomib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	8.48e-05	0.000584	CcSEcCtD
Bortezomib—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	8.47e-05	0.000583	CcSEcCtD
Bortezomib—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	8.44e-05	0.000581	CcSEcCtD
Bortezomib—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	8.43e-05	0.00058	CcSEcCtD
Bortezomib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	8.4e-05	0.000578	CcSEcCtD
Bortezomib—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	8.36e-05	0.000576	CcSEcCtD
Bortezomib—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	8.36e-05	0.000576	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	8.35e-05	0.000574	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	8.35e-05	0.000574	CcSEcCtD
Bortezomib—Insomnia—Formoterol—chronic obstructive pulmonary disease	8.29e-05	0.00057	CcSEcCtD
Bortezomib—Insomnia—Arformoterol—chronic obstructive pulmonary disease	8.29e-05	0.00057	CcSEcCtD
Bortezomib—Anorexia—Salbutamol—chronic obstructive pulmonary disease	8.25e-05	0.000567	CcSEcCtD
Bortezomib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	8.24e-05	0.000567	CcSEcCtD
Bortezomib—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	8.2e-05	0.000564	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	8.18e-05	0.000563	CcSEcCtD
Bortezomib—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	8.17e-05	0.000562	CcSEcCtD
Bortezomib—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	8.17e-05	0.000562	CcSEcCtD
Bortezomib—Insomnia—Montelukast—chronic obstructive pulmonary disease	8.12e-05	0.000559	CcSEcCtD
Bortezomib—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	8.09e-05	0.000557	CcSEcCtD
Bortezomib—Hypotension—Salbutamol—chronic obstructive pulmonary disease	8.08e-05	0.000556	CcSEcCtD
Bortezomib—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	8.06e-05	0.000555	CcSEcCtD
Bortezomib—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	8.06e-05	0.000555	CcSEcCtD
Bortezomib—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	8.06e-05	0.000555	CcSEcCtD
Bortezomib—Pruritus—Tiotropium—chronic obstructive pulmonary disease	8.03e-05	0.000553	CcSEcCtD
Bortezomib—Dizziness—Aminophylline—chronic obstructive pulmonary disease	7.96e-05	0.000548	CcSEcCtD
Bortezomib—Weight increased—Prednisolone—chronic obstructive pulmonary disease	7.94e-05	0.000546	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	7.91e-05	0.000544	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	7.91e-05	0.000544	CcSEcCtD
Bortezomib—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	7.9e-05	0.000544	CcSEcCtD
Bortezomib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	7.9e-05	0.000544	CcSEcCtD
Bortezomib—Fatigue—Formoterol—chronic obstructive pulmonary disease	7.9e-05	0.000544	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	7.88e-05	0.000542	CcSEcCtD
Bortezomib—Pain—Arformoterol—chronic obstructive pulmonary disease	7.83e-05	0.000539	CcSEcCtD
Bortezomib—Pain—Formoterol—chronic obstructive pulmonary disease	7.83e-05	0.000539	CcSEcCtD
Bortezomib—Constipation—Formoterol—chronic obstructive pulmonary disease	7.83e-05	0.000539	CcSEcCtD
Bortezomib—Constipation—Arformoterol—chronic obstructive pulmonary disease	7.83e-05	0.000539	CcSEcCtD
Bortezomib—Insomnia—Salbutamol—chronic obstructive pulmonary disease	7.82e-05	0.000538	CcSEcCtD
Bortezomib—Increased appetite—Prednisone—chronic obstructive pulmonary disease	7.81e-05	0.000537	CcSEcCtD
Bortezomib—Amnesia—Prednisone—chronic obstructive pulmonary disease	7.81e-05	0.000537	CcSEcCtD
Bortezomib—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	7.77e-05	0.000535	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	7.75e-05	0.000533	CcSEcCtD
Bortezomib—Fatigue—Montelukast—chronic obstructive pulmonary disease	7.74e-05	0.000532	CcSEcCtD
Bortezomib—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	7.71e-05	0.000531	CcSEcCtD
Bortezomib—Pain—Montelukast—chronic obstructive pulmonary disease	7.67e-05	0.000528	CcSEcCtD
Bortezomib—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	7.67e-05	0.000528	CcSEcCtD
Bortezomib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	7.65e-05	0.000527	CcSEcCtD
Bortezomib—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	7.63e-05	0.000525	CcSEcCtD
Bortezomib—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	7.63e-05	0.000525	CcSEcCtD
Bortezomib—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	7.61e-05	0.000524	CcSEcCtD
Bortezomib—Purpura—Prednisone—chronic obstructive pulmonary disease	7.61e-05	0.000524	CcSEcCtD
Bortezomib—Rash—Aminophylline—chronic obstructive pulmonary disease	7.59e-05	0.000522	CcSEcCtD
Bortezomib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	7.58e-05	0.000522	CcSEcCtD
Bortezomib—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	7.56e-05	0.00052	CcSEcCtD
Bortezomib—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	7.55e-05	0.00052	CcSEcCtD
Bortezomib—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	7.55e-05	0.00052	CcSEcCtD
Bortezomib—Headache—Aminophylline—chronic obstructive pulmonary disease	7.54e-05	0.000519	CcSEcCtD
Bortezomib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	7.52e-05	0.000518	CcSEcCtD
Bortezomib—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	7.52e-05	0.000517	CcSEcCtD
Bortezomib—Dizziness—Tiotropium—chronic obstructive pulmonary disease	7.51e-05	0.000517	CcSEcCtD
Bortezomib—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	7.49e-05	0.000516	CcSEcCtD
Bortezomib—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	7.49e-05	0.000516	CcSEcCtD
Bortezomib—Lethargy—Prednisone—chronic obstructive pulmonary disease	7.49e-05	0.000515	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	7.47e-05	0.000514	CcSEcCtD
Bortezomib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	7.46e-05	0.000513	CcSEcCtD
Bortezomib—Pain—Salbutamol—chronic obstructive pulmonary disease	7.4e-05	0.000509	CcSEcCtD
Bortezomib—Constipation—Salbutamol—chronic obstructive pulmonary disease	7.4e-05	0.000509	CcSEcCtD
Bortezomib—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	7.34e-05	0.000505	CcSEcCtD
Bortezomib—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	7.34e-05	0.000505	CcSEcCtD
Bortezomib—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	7.34e-05	0.000505	CcSEcCtD
Bortezomib—Urticaria—Formoterol—chronic obstructive pulmonary disease	7.28e-05	0.000501	CcSEcCtD
Bortezomib—Urticaria—Arformoterol—chronic obstructive pulmonary disease	7.28e-05	0.000501	CcSEcCtD
Bortezomib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	7.24e-05	0.000498	CcSEcCtD
Bortezomib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	7.24e-05	0.000498	CcSEcCtD
Bortezomib—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	7.24e-05	0.000498	CcSEcCtD
Bortezomib—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	7.24e-05	0.000498	CcSEcCtD
Bortezomib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	7.22e-05	0.000497	CcSEcCtD
Bortezomib—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	7.16e-05	0.000493	CcSEcCtD
Bortezomib—Rash—Tiotropium—chronic obstructive pulmonary disease	7.16e-05	0.000493	CcSEcCtD
Bortezomib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	7.15e-05	0.000492	CcSEcCtD
Bortezomib—Nausea—Aminophylline—chronic obstructive pulmonary disease	7.15e-05	0.000492	CcSEcCtD
Bortezomib—Urticaria—Montelukast—chronic obstructive pulmonary disease	7.13e-05	0.000491	CcSEcCtD
Bortezomib—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	7.13e-05	0.000491	CcSEcCtD
Bortezomib—Headache—Tiotropium—chronic obstructive pulmonary disease	7.11e-05	0.000489	CcSEcCtD
Bortezomib—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	7.11e-05	0.000489	CcSEcCtD
Bortezomib—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	7.09e-05	0.000488	CcSEcCtD
Bortezomib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	7.09e-05	0.000488	CcSEcCtD
Bortezomib—Face oedema—Prednisone—chronic obstructive pulmonary disease	7.08e-05	0.000487	CcSEcCtD
Bortezomib—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	7.07e-05	0.000487	CcSEcCtD
Bortezomib—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	7.02e-05	0.000483	CcSEcCtD
Bortezomib—Irritability—Prednisone—chronic obstructive pulmonary disease	7e-05	0.000482	CcSEcCtD
Bortezomib—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	6.98e-05	0.000481	CcSEcCtD
Bortezomib—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	6.98e-05	0.00048	CcSEcCtD
Bortezomib—Urticaria—Salbutamol—chronic obstructive pulmonary disease	6.87e-05	0.000473	CcSEcCtD
Bortezomib—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	6.84e-05	0.000471	CcSEcCtD
Bortezomib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	6.84e-05	0.000471	CcSEcCtD
Bortezomib—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	6.75e-05	0.000465	CcSEcCtD
Bortezomib—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	6.75e-05	0.000465	CcSEcCtD
Bortezomib—Nausea—Tiotropium—chronic obstructive pulmonary disease	6.74e-05	0.000464	CcSEcCtD
Bortezomib—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	6.73e-05	0.000463	CcSEcCtD
Bortezomib—Dry skin—Prednisone—chronic obstructive pulmonary disease	6.72e-05	0.000463	CcSEcCtD
Bortezomib—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	6.68e-05	0.000459	CcSEcCtD
Bortezomib—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	6.61e-05	0.000455	CcSEcCtD
Bortezomib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	6.57e-05	0.000452	CcSEcCtD
Bortezomib—Asthenia—Formoterol—chronic obstructive pulmonary disease	6.57e-05	0.000452	CcSEcCtD
Bortezomib—Pruritus—Formoterol—chronic obstructive pulmonary disease	6.48e-05	0.000446	CcSEcCtD
Bortezomib—Pruritus—Arformoterol—chronic obstructive pulmonary disease	6.48e-05	0.000446	CcSEcCtD
Bortezomib—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	6.47e-05	0.000445	CcSEcCtD
Bortezomib—Asthenia—Montelukast—chronic obstructive pulmonary disease	6.44e-05	0.000443	CcSEcCtD
Bortezomib—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	6.38e-05	0.000439	CcSEcCtD
Bortezomib—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	6.37e-05	0.000439	CcSEcCtD
Bortezomib—Pruritus—Montelukast—chronic obstructive pulmonary disease	6.35e-05	0.000437	CcSEcCtD
Bortezomib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	6.27e-05	0.000431	CcSEcCtD
Bortezomib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	6.27e-05	0.000431	CcSEcCtD
Bortezomib—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	6.24e-05	0.000429	CcSEcCtD
Bortezomib—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	6.22e-05	0.000428	CcSEcCtD
Bortezomib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	6.21e-05	0.000427	CcSEcCtD
Bortezomib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	6.14e-05	0.000423	CcSEcCtD
Bortezomib—Pruritus—Salbutamol—chronic obstructive pulmonary disease	6.12e-05	0.000421	CcSEcCtD
Bortezomib—Erythema—Prednisolone—chronic obstructive pulmonary disease	6.08e-05	0.000418	CcSEcCtD
Bortezomib—Dizziness—Arformoterol—chronic obstructive pulmonary disease	6.06e-05	0.000417	CcSEcCtD
Bortezomib—Dizziness—Formoterol—chronic obstructive pulmonary disease	6.06e-05	0.000417	CcSEcCtD
Bortezomib—Dizziness—Montelukast—chronic obstructive pulmonary disease	5.93e-05	0.000408	CcSEcCtD
Bortezomib—Neutropenia—Prednisone—chronic obstructive pulmonary disease	5.93e-05	0.000408	CcSEcCtD
Bortezomib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	5.92e-05	0.000407	CcSEcCtD
Bortezomib—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	5.84e-05	0.000402	CcSEcCtD
Bortezomib—Vomiting—Formoterol—chronic obstructive pulmonary disease	5.82e-05	0.000401	CcSEcCtD
Bortezomib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	5.82e-05	0.000401	CcSEcCtD
Bortezomib—Rash—Arformoterol—chronic obstructive pulmonary disease	5.78e-05	0.000398	CcSEcCtD
Bortezomib—Rash—Formoterol—chronic obstructive pulmonary disease	5.78e-05	0.000398	CcSEcCtD
Bortezomib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	5.77e-05	0.000397	CcSEcCtD
Bortezomib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	5.77e-05	0.000397	CcSEcCtD
Bortezomib—Weight increased—Prednisone—chronic obstructive pulmonary disease	5.77e-05	0.000397	CcSEcCtD
Bortezomib—Headache—Arformoterol—chronic obstructive pulmonary disease	5.74e-05	0.000395	CcSEcCtD
Bortezomib—Headache—Formoterol—chronic obstructive pulmonary disease	5.74e-05	0.000395	CcSEcCtD
Bortezomib—Weight decreased—Prednisone—chronic obstructive pulmonary disease	5.74e-05	0.000395	CcSEcCtD
Bortezomib—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	5.73e-05	0.000394	CcSEcCtD
Bortezomib—Dizziness—Salbutamol—chronic obstructive pulmonary disease	5.72e-05	0.000394	CcSEcCtD
Bortezomib—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	5.72e-05	0.000394	CcSEcCtD
Bortezomib—Vomiting—Montelukast—chronic obstructive pulmonary disease	5.71e-05	0.000393	CcSEcCtD
Bortezomib—Rash—Montelukast—chronic obstructive pulmonary disease	5.66e-05	0.000389	CcSEcCtD
Bortezomib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	5.65e-05	0.000389	CcSEcCtD
Bortezomib—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	5.64e-05	0.000388	CcSEcCtD
Bortezomib—Headache—Montelukast—chronic obstructive pulmonary disease	5.62e-05	0.000387	CcSEcCtD
Bortezomib—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	5.57e-05	0.000384	CcSEcCtD
Bortezomib—Angioedema—Prednisolone—chronic obstructive pulmonary disease	5.55e-05	0.000382	CcSEcCtD
Bortezomib—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	5.54e-05	0.000381	CcSEcCtD
Bortezomib—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	5.54e-05	0.000381	CcSEcCtD
Bortezomib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	5.5e-05	0.000379	CcSEcCtD
Bortezomib—Malaise—Prednisolone—chronic obstructive pulmonary disease	5.48e-05	0.000377	CcSEcCtD
Bortezomib—Vertigo—Prednisolone—chronic obstructive pulmonary disease	5.46e-05	0.000376	CcSEcCtD
Bortezomib—Rash—Salbutamol—chronic obstructive pulmonary disease	5.45e-05	0.000375	CcSEcCtD
Bortezomib—Syncope—Prednisolone—chronic obstructive pulmonary disease	5.45e-05	0.000375	CcSEcCtD
Bortezomib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	5.45e-05	0.000375	CcSEcCtD
Bortezomib—Nausea—Formoterol—chronic obstructive pulmonary disease	5.44e-05	0.000375	CcSEcCtD
Bortezomib—Nausea—Arformoterol—chronic obstructive pulmonary disease	5.44e-05	0.000375	CcSEcCtD
Bortezomib—Headache—Salbutamol—chronic obstructive pulmonary disease	5.42e-05	0.000373	CcSEcCtD
Bortezomib—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	5.34e-05	0.000368	CcSEcCtD
Bortezomib—Nausea—Montelukast—chronic obstructive pulmonary disease	5.33e-05	0.000367	CcSEcCtD
Bortezomib—Convulsion—Prednisolone—chronic obstructive pulmonary disease	5.27e-05	0.000363	CcSEcCtD
Bortezomib—Hypertension—Prednisolone—chronic obstructive pulmonary disease	5.25e-05	0.000361	CcSEcCtD
Bortezomib—Bradycardia—Prednisone—chronic obstructive pulmonary disease	5.17e-05	0.000356	CcSEcCtD
Bortezomib—Nausea—Salbutamol—chronic obstructive pulmonary disease	5.14e-05	0.000354	CcSEcCtD
Bortezomib—Discomfort—Prednisolone—chronic obstructive pulmonary disease	5.11e-05	0.000352	CcSEcCtD
Bortezomib—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	5.1e-05	0.000351	CcSEcCtD
Bortezomib—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	5.07e-05	0.000349	CcSEcCtD
Bortezomib—Hallucination—Prednisone—chronic obstructive pulmonary disease	5.05e-05	0.000348	CcSEcCtD
Bortezomib—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	4.99e-05	0.000343	CcSEcCtD
Bortezomib—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	4.96e-05	0.000341	CcSEcCtD
Bortezomib—Oedema—Prednisolone—chronic obstructive pulmonary disease	4.96e-05	0.000341	CcSEcCtD
Bortezomib—Shock—Prednisolone—chronic obstructive pulmonary disease	4.88e-05	0.000336	CcSEcCtD
Bortezomib—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	4.84e-05	0.000333	CcSEcCtD
Bortezomib—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	4.8e-05	0.00033	CcSEcCtD
Bortezomib—Eye disorder—Prednisone—chronic obstructive pulmonary disease	4.74e-05	0.000326	CcSEcCtD
Bortezomib—Flushing—Prednisone—chronic obstructive pulmonary disease	4.71e-05	0.000324	CcSEcCtD
Bortezomib—Angiopathy—Prednisone—chronic obstructive pulmonary disease	4.6e-05	0.000317	CcSEcCtD
Bortezomib—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	4.58e-05	0.000315	CcSEcCtD
Bortezomib—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	4.53e-05	0.000312	CcSEcCtD
Bortezomib—Insomnia—Prednisolone—chronic obstructive pulmonary disease	4.49e-05	0.000309	CcSEcCtD
Bortezomib—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	4.46e-05	0.000307	CcSEcCtD
Bortezomib—Mental disorder—Prednisone—chronic obstructive pulmonary disease	4.45e-05	0.000306	CcSEcCtD
Bortezomib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	4.42e-05	0.000304	CcSEcCtD
Bortezomib—Erythema—Prednisone—chronic obstructive pulmonary disease	4.42e-05	0.000304	CcSEcCtD
Bortezomib—Pain—Prednisolone—chronic obstructive pulmonary disease	4.24e-05	0.000292	CcSEcCtD
Bortezomib—Vision blurred—Prednisone—chronic obstructive pulmonary disease	4.16e-05	0.000287	CcSEcCtD
Bortezomib—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	4.1e-05	0.000282	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	4.09e-05	0.000281	CcSEcCtD
Bortezomib—Anaemia—Prednisone—chronic obstructive pulmonary disease	4.08e-05	0.000281	CcSEcCtD
Bortezomib—Agitation—Prednisone—chronic obstructive pulmonary disease	4.06e-05	0.000279	CcSEcCtD
Bortezomib—Angioedema—Prednisone—chronic obstructive pulmonary disease	4.04e-05	0.000278	CcSEcCtD
Bortezomib—Malaise—Prednisone—chronic obstructive pulmonary disease	3.98e-05	0.000274	CcSEcCtD
Bortezomib—Vertigo—Prednisone—chronic obstructive pulmonary disease	3.97e-05	0.000273	CcSEcCtD
Bortezomib—Syncope—Prednisone—chronic obstructive pulmonary disease	3.96e-05	0.000273	CcSEcCtD
Bortezomib—Urticaria—Prednisolone—chronic obstructive pulmonary disease	3.94e-05	0.000271	CcSEcCtD
Bortezomib—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	3.88e-05	0.000267	CcSEcCtD
Bortezomib—Convulsion—Prednisone—chronic obstructive pulmonary disease	3.83e-05	0.000263	CcSEcCtD
Bortezomib—Hypertension—Prednisone—chronic obstructive pulmonary disease	3.81e-05	0.000262	CcSEcCtD
Bortezomib—Myalgia—Prednisone—chronic obstructive pulmonary disease	3.76e-05	0.000259	CcSEcCtD
Bortezomib—Arthralgia—Prednisone—chronic obstructive pulmonary disease	3.76e-05	0.000259	CcSEcCtD
Bortezomib—Anxiety—Prednisone—chronic obstructive pulmonary disease	3.75e-05	0.000258	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	3.74e-05	0.000257	CcSEcCtD
Bortezomib—Discomfort—Prednisone—chronic obstructive pulmonary disease	3.72e-05	0.000256	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	3.66e-05	0.000252	CcSEcCtD
Bortezomib—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	3.61e-05	0.000248	CcSEcCtD
Bortezomib—Oedema—Prednisone—chronic obstructive pulmonary disease	3.61e-05	0.000248	CcSEcCtD
Bortezomib—Infection—Prednisone—chronic obstructive pulmonary disease	3.58e-05	0.000247	CcSEcCtD
Bortezomib—Shock—Prednisone—chronic obstructive pulmonary disease	3.55e-05	0.000244	CcSEcCtD
Bortezomib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	3.54e-05	0.000243	CcSEcCtD
Bortezomib—Tachycardia—Prednisone—chronic obstructive pulmonary disease	3.52e-05	0.000242	CcSEcCtD
Bortezomib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	3.5e-05	0.000241	CcSEcCtD
Bortezomib—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	3.49e-05	0.00024	CcSEcCtD
Bortezomib—Anorexia—Prednisone—chronic obstructive pulmonary disease	3.44e-05	0.000237	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	3.28e-05	0.000226	CcSEcCtD
Bortezomib—Dizziness—Prednisolone—chronic obstructive pulmonary disease	3.28e-05	0.000226	CcSEcCtD
Bortezomib—Insomnia—Prednisone—chronic obstructive pulmonary disease	3.26e-05	0.000224	CcSEcCtD
Bortezomib—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	3.24e-05	0.000223	CcSEcCtD
Bortezomib—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	3.17e-05	0.000218	CcSEcCtD
Bortezomib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	3.13e-05	0.000216	CcSEcCtD
Bortezomib—Rash—Prednisolone—chronic obstructive pulmonary disease	3.13e-05	0.000215	CcSEcCtD
Bortezomib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	3.13e-05	0.000215	CcSEcCtD
Bortezomib—Fatigue—Prednisone—chronic obstructive pulmonary disease	3.11e-05	0.000214	CcSEcCtD
Bortezomib—Headache—Prednisolone—chronic obstructive pulmonary disease	3.11e-05	0.000214	CcSEcCtD
Bortezomib—Constipation—Prednisone—chronic obstructive pulmonary disease	3.08e-05	0.000212	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	2.97e-05	0.000204	CcSEcCtD
Bortezomib—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	2.95e-05	0.000203	CcSEcCtD
Bortezomib—Nausea—Prednisolone—chronic obstructive pulmonary disease	2.95e-05	0.000203	CcSEcCtD
Bortezomib—Urticaria—Prednisone—chronic obstructive pulmonary disease	2.86e-05	0.000197	CcSEcCtD
Bortezomib—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	2.85e-05	0.000196	CcSEcCtD
Bortezomib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	2.85e-05	0.000196	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	2.66e-05	0.000183	CcSEcCtD
Bortezomib—Asthenia—Prednisone—chronic obstructive pulmonary disease	2.59e-05	0.000178	CcSEcCtD
Bortezomib—Pruritus—Prednisone—chronic obstructive pulmonary disease	2.55e-05	0.000176	CcSEcCtD
Bortezomib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	2.47e-05	0.00017	CcSEcCtD
Bortezomib—Dizziness—Prednisone—chronic obstructive pulmonary disease	2.38e-05	0.000164	CcSEcCtD
Bortezomib—Vomiting—Prednisone—chronic obstructive pulmonary disease	2.29e-05	0.000158	CcSEcCtD
Bortezomib—Rash—Prednisone—chronic obstructive pulmonary disease	2.27e-05	0.000156	CcSEcCtD
Bortezomib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	2.27e-05	0.000156	CcSEcCtD
Bortezomib—Headache—Prednisone—chronic obstructive pulmonary disease	2.26e-05	0.000155	CcSEcCtD
Bortezomib—Nausea—Prednisone—chronic obstructive pulmonary disease	2.14e-05	0.000147	CcSEcCtD
Bortezomib—PSMB2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.28e-05	0.000139	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.28e-05	0.000139	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—ALB—chronic obstructive pulmonary disease	1.27e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	1.27e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.26e-05	0.000137	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	1.25e-05	0.000136	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	1.25e-05	0.000136	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	1.25e-05	0.000136	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.24e-05	0.000134	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.24e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	1.23e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.23e-05	0.000133	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.22e-05	0.000133	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.22e-05	0.000133	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.22e-05	0.000133	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.22e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—NOS3—chronic obstructive pulmonary disease	1.21e-05	0.000132	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.21e-05	0.000132	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.21e-05	0.000132	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.2e-05	0.00013	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.19e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—chronic obstructive pulmonary disease	1.18e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—chronic obstructive pulmonary disease	1.18e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—chronic obstructive pulmonary disease	1.18e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB1—Disease—SERPINE1—chronic obstructive pulmonary disease	1.16e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMB5—Disease—SERPINE1—chronic obstructive pulmonary disease	1.16e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMB2—Disease—SERPINE1—chronic obstructive pulmonary disease	1.16e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—chronic obstructive pulmonary disease	1.16e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.16e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.16e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.16e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMB8—Disease—SERPINE1—chronic obstructive pulmonary disease	1.15e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.14e-05	0.000124	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.14e-05	0.000124	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.13e-05	0.000122	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.12e-05	0.000121	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.12e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.12e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.12e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.12e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NOS3—chronic obstructive pulmonary disease	1.11e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NOS3—chronic obstructive pulmonary disease	1.11e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NOS3—chronic obstructive pulmonary disease	1.11e-05	0.000121	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.11e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.1e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NOS3—chronic obstructive pulmonary disease	1.09e-05	0.000119	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.08e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.07e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.07e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.06e-05	0.000116	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.05e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.04e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.04e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.04e-05	0.000113	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.03e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—EGFR—chronic obstructive pulmonary disease	1.03e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.03e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—EGFR—chronic obstructive pulmonary disease	1.02e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL1B—chronic obstructive pulmonary disease	1.02e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL1B—chronic obstructive pulmonary disease	1.02e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL1B—chronic obstructive pulmonary disease	1.02e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.02e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.02e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—EGFR—chronic obstructive pulmonary disease	1.02e-05	0.000111	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.02e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.02e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL1B—chronic obstructive pulmonary disease	1.01e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—ALB—chronic obstructive pulmonary disease	9.72e-06	0.000106	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ALB—chronic obstructive pulmonary disease	9.72e-06	0.000106	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ALB—chronic obstructive pulmonary disease	9.72e-06	0.000106	CbGpPWpGaD
Bortezomib—PSMA1—Disease—TGFB1—chronic obstructive pulmonary disease	9.68e-06	0.000105	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.68e-06	0.000105	CbGpPWpGaD
Bortezomib—PSMD1—Disease—TGFB1—chronic obstructive pulmonary disease	9.64e-06	0.000105	CbGpPWpGaD
Bortezomib—PSMD2—Disease—TGFB1—chronic obstructive pulmonary disease	9.59e-06	0.000104	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—ALB—chronic obstructive pulmonary disease	9.58e-06	0.000104	CbGpPWpGaD
Bortezomib—PSMA1—Disease—EGFR—chronic obstructive pulmonary disease	9.5e-06	0.000103	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.46e-06	0.000103	CbGpPWpGaD
Bortezomib—PSMD1—Disease—EGFR—chronic obstructive pulmonary disease	9.45e-06	0.000103	CbGpPWpGaD
Bortezomib—PSMD2—Disease—EGFR—chronic obstructive pulmonary disease	9.41e-06	0.000102	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—NOS3—chronic obstructive pulmonary disease	9.3e-06	0.000101	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—NOS3—chronic obstructive pulmonary disease	9.3e-06	0.000101	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—NOS3—chronic obstructive pulmonary disease	9.3e-06	0.000101	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—NOS3—chronic obstructive pulmonary disease	9.16e-06	9.95e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.1e-06	9.88e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.05e-06	9.83e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.01e-06	9.78e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	8.82e-06	9.58e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.72e-06	9.47e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	8.62e-06	9.36e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.58e-06	9.32e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.46e-06	9.19e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.23e-06	8.93e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.19e-06	8.89e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.15e-06	8.85e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.14e-06	8.84e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.14e-06	8.84e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.14e-06	8.84e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	8.07e-06	8.77e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.04e-06	8.73e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.03e-06	8.72e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.99e-06	8.68e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL6—chronic obstructive pulmonary disease	7.9e-06	8.58e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	7.9e-06	8.58e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.88e-06	8.56e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL6—chronic obstructive pulmonary disease	7.87e-06	8.54e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	7.87e-06	8.54e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	7.85e-06	8.53e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL6—chronic obstructive pulmonary disease	7.83e-06	8.5e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—EGFR—chronic obstructive pulmonary disease	7.79e-06	8.46e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—EGFR—chronic obstructive pulmonary disease	7.79e-06	8.46e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—EGFR—chronic obstructive pulmonary disease	7.79e-06	8.46e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.77e-06	8.44e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.77e-06	8.44e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.77e-06	8.44e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EGFR—chronic obstructive pulmonary disease	7.68e-06	8.34e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.66e-06	8.32e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	7.54e-06	8.19e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.47e-06	8.12e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.39e-06	8.02e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.37e-06	8e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.35e-06	7.98e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFB1—chronic obstructive pulmonary disease	7.34e-06	7.97e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFB1—chronic obstructive pulmonary disease	7.34e-06	7.97e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFB1—chronic obstructive pulmonary disease	7.34e-06	7.97e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.32e-06	7.95e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.3e-06	7.93e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—IL6—chronic obstructive pulmonary disease	7.3e-06	7.92e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—IL6—chronic obstructive pulmonary disease	7.26e-06	7.89e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.25e-06	7.87e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFB1—chronic obstructive pulmonary disease	7.24e-06	7.86e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—IL6—chronic obstructive pulmonary disease	7.23e-06	7.85e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	7.21e-06	7.83e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EGFR—chronic obstructive pulmonary disease	7.2e-06	7.81e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EGFR—chronic obstructive pulmonary disease	7.2e-06	7.81e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EGFR—chronic obstructive pulmonary disease	7.2e-06	7.81e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.14e-06	7.75e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EGFR—chronic obstructive pulmonary disease	7.09e-06	7.7e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	7.05e-06	7.66e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.89e-06	7.49e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.89e-06	7.49e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.89e-06	7.49e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.8e-06	7.38e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.78e-06	7.36e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.75e-06	7.33e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.72e-06	7.29e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.65e-06	7.22e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.64e-06	7.21e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.62e-06	7.19e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.59e-06	7.15e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.58e-06	7.14e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.56e-06	7.13e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.51e-06	7.07e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	6.49e-06	7.04e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	6.44e-06	6.99e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	6.43e-06	6.98e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.24e-06	6.77e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.24e-06	6.77e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.24e-06	6.77e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.15e-06	6.68e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.04e-06	6.56e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6e-06	6.51e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—chronic obstructive pulmonary disease	5.99e-06	6.5e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—chronic obstructive pulmonary disease	5.99e-06	6.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—chronic obstructive pulmonary disease	5.99e-06	6.5e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.96e-06	6.47e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.93e-06	6.44e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	5.92e-06	6.43e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—chronic obstructive pulmonary disease	5.91e-06	6.41e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	5.87e-06	6.37e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.6e-06	6.08e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.6e-06	6.08e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.6e-06	6.08e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.58e-06	6.06e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.56e-06	6.04e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.56e-06	6.03e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.55e-06	6.03e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.54e-06	6.02e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—chronic obstructive pulmonary disease	5.53e-06	6.01e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—chronic obstructive pulmonary disease	5.53e-06	6.01e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—chronic obstructive pulmonary disease	5.53e-06	6.01e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.53e-06	6e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.52e-06	5.99e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	5.5e-06	5.97e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.47e-06	5.93e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.45e-06	5.92e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—chronic obstructive pulmonary disease	5.45e-06	5.92e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.41e-06	5.87e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.14e-06	5.58e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.14e-06	5.58e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.14e-06	5.58e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.12e-06	5.56e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.11e-06	5.55e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.09e-06	5.53e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.09e-06	5.52e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—chronic obstructive pulmonary disease	5.08e-06	5.52e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.07e-06	5.5e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.06e-06	5.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.04e-06	5.47e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.04e-06	5.47e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.04e-06	5.47e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	5.02e-06	5.45e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.97e-06	5.39e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.95e-06	5.37e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.88e-06	5.3e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.86e-06	5.28e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.83e-06	5.24e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.55e-06	4.94e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.55e-06	4.94e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.51e-06	4.9e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.49e-06	4.87e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.45e-06	4.83e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.31e-06	4.68e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.29e-06	4.66e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	4.24e-06	4.61e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.23e-06	4.59e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.23e-06	4.59e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.23e-06	4.59e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.18e-06	4.54e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.17e-06	4.53e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.14e-06	4.5e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.96e-06	4.3e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.93e-06	4.27e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.87e-06	4.21e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.87e-06	4.21e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.87e-06	4.21e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	3.87e-06	4.2e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.85e-06	4.18e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.82e-06	4.15e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.8e-06	4.13e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—chronic obstructive pulmonary disease	3.58e-06	3.89e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.57e-06	3.87e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.54e-06	3.85e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.42e-06	3.72e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.36e-06	3.65e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	3.28e-06	3.56e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	3.14e-06	3.41e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.97e-06	3.23e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.93e-06	3.19e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	2.93e-06	3.18e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	2.8e-06	3.04e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.73e-06	2.97e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	2.69e-06	2.93e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	2.67e-06	2.9e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.59e-06	2.81e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.58e-06	2.8e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.55e-06	2.77e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.28e-06	2.48e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.18e-06	2.37e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.76e-06	1.91e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.68e-06	1.83e-05	CbGpPWpGaD
